About 40,000 professionals from all over the world gathered in Chicago on the occasion of ASCO 2017 (53rd Congress of the American Society of Clinical Oncology) from June 2-6 a multitudinous event in which both diagnostic and therapeutic advances against cancer and the results of multiple ongoing studies on the disease were presented. Reduce the fear associated and coexistence with cancer; Treatments with immunotherapy and personalized medicine were the most relevant discussions of the congress.
Among the news in cancer treatments and approaches, HC Marbella’s Oncology Unit chief, Dr. Hernán Cortés-Funes, confirms the usefulness of immunotherapy in lung cancer and other tumors such as melanoma, renal carcinoma , urothelial carcinoma (bladder), pleural mesothelioma, head and neck cancer, Hodgkin’s lymphoma, gynecological tumors and gastric carcinoma. “Immunotherapy is becoming the most effective treatment for the advanced disease or relapses; better than chemotherapy and other biological treatments, increasing the hope and quality of life for patients, “explains Dr. Cortés-Funes”. But in addition, “combined immunotherapy with the same chemotherapy or with other immunotherapeutic agents, may be a way to improve the options of many patients,” he said.
The technique of CALM psychotherapy, as an aid to patients in very advanced stages of the disease; this was one of the most relevant studies presented in ASCO 2017 to help overcome a depression during the disease. In the opinion of Dr. Cortés-Funes, “effectively the psicoterapia is extremely important to make the patient understand the illness, lose the fear and fight it in all of its stages.”
We ask our head of medical team about the possibility of greater survival in the future thanks to immunology, personalized medicine is the key: “to individualize the treatments it is important the knowledge of the genetic-molecular profiles of the tumors, through the most rational study of each case. Thus, we can diagnose the disease more simply through the determination in blood of circulating tumor cells or circulating DNA (liquid biopsy), which carries mutations sensitive to biological treatments, “he concludes.
June 9, 2017
Read other news